Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets.

Rapamycin (sirolimus) is a macrolide fungicide with immunosuppressant properties that is used in human islet transplantation. Little is known about the effects of rapamycin on MIN-6 cells and islets. Rapamycin had a dose-dependent, time-dependent, and glucose-independent deleterious effect on MIN-6 cell viability. At day 1, using the MTT method, 0.01 nmol/l rapamycin reduced cell viability to 83 +/- 6% of control (P < 0.05). Using the calcein AM method, at day 2, 10 nmol/l rapamycin caused a reduction in cell viability to 73 +/- 5% of control (P < 0.001). Furthermore, 10 and 100 nmol/l rapamycin caused apoptosis in MIN-6 cells as assessed by the transferase-mediated dUTP nick-end labeling assay. Compared with control, there was a 3.1 +/- 0.6-fold increase (P < 0.01) in apoptosis in MIN-6 cells treated with 10 nmol/l rapamycin. A supra-therapeutic rapamycin concentration of 100 nmol/l significantly impaired glucose- and carbachol-stimulated insulin secretion in rat islets and had a deleterious effect on the viability of rat and human islets, causing apoptosis of both alpha- and beta-cells.

[1]  G. Mills,et al.  Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. , 1995, Cancer research.

[2]  B. Wolf,et al.  Synaptotagmin III/VII Isoforms Mediate Ca2+-induced Insulin Secretion in Pancreatic Islet β-Cells* , 2000, The Journal of Biological Chemistry.

[3]  E. Ryan,et al.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. , 2000, The New England journal of medicine.

[4]  S. Muthukkumar,et al.  RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS , 1995, Transplantation.

[5]  B. Kiberd,et al.  Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: effect on renal function. , 2001, Transplantation proceedings.

[6]  A. M. Shapiro,et al.  Portal vein immunosuppressant levels and islet graft toxicity. , 1998, Transplantation proceedings.

[7]  J. Barata,et al.  Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). , 2001, Blood.

[8]  G. Everson,et al.  Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[9]  J. D. de Fijter,et al.  Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. , 2001, Blood.

[10]  R. Robertson,et al.  INHIBITORY EFFECTS OF IMMUNOSUPPRESSIVE DRUGS ON INSULIN SECRETION FROM HIT-T15 CELLS AND WISTAR RAT ISLETS1 , 2002, Transplantation.

[11]  G. Snell,et al.  Rescue therapy: a role for sirolimus in lung and heart transplant recipients. , 2001, Transplantation proceedings.

[12]  T. Seufferlein,et al.  Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. , 1996, Cancer research.

[13]  S. Stepkowski,et al.  The development of sirolimus: The University of Texas-Houston experience. , 2000, Clinical transplants.

[14]  Paul Tempst,et al.  RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs , 1994, Cell.

[15]  B. Kaplan,et al.  RAD IN DE NOVO RENAL TRANSPLANTATION: COMPARISON OF THREE DOSES ON THE INCIDENCE AND SEVERITY OF ACUTE REJECTION 1 , 2001, Transplantation.

[16]  Benno J. Rensing,et al.  Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.

[17]  Christine C. Hudson,et al.  Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. , 1997, Science.

[18]  Linda N. Liu,et al.  Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. , 1999, Cancer research.

[19]  L. Shaw,et al.  Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview. , 2000, Clinical therapeutics.

[20]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[21]  P. Lacy,et al.  A subcellular fractionation approach for studying insulin release mechanisms and calcium metabolism in islets of Langerhans. , 1983, Methods in enzymology.

[22]  R. Perugini,et al.  FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. , 2001, The Journal of surgical research.

[23]  H. Schuurman,et al.  Effect of rapamycin on islet xenograft survival. , 1994, Transplantation proceedings.

[24]  P. Tsao,et al.  Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.

[25]  M. Mann,et al.  p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  F. Neumann,et al.  Gene Expression Profiling of Human Stent-Induced Neointima by cDNA Array Analysis of Microscopic Specimens Retrieved by Helix Cutter Atherectomy: Detection of FK506-Binding Protein 12 Upregulation , 2001, Circulation.

[27]  D. Finegood,et al.  The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. , 1996, Transplantation.